Spengler Mary L, Brattain Michael G
Department of Pharmacology and Therapeutics, Roswell Park Cancer Institute, Elm and Carlton Streets, Buffalo, NY 14263, USA.
J Biol Chem. 2006 Mar 3;281(9):5567-74. doi: 10.1074/jbc.M600035200. Epub 2006 Jan 5.
Sp1 is a ubiquitously expressed transcription factor that binds GC-rich cis elements. Many posttranslational modifications have been implicated in the regulation of Sp1 activity. We now provide evidence for a novel mechanism of Sp1 regulation involving the small ubiquitin-like modifier (SUMO-1). Western blot analysis revealed a high molecular mass Sp1 of 125 kDa that is stabilized by a selective SUMO hydrolase inhibitor and destabilized by a specific SUMO-1 hydrolase. The covalent modification of Sp1 by endogenous SUMO-1 and SUMO-1 that has been fused to green fluorescent protein was demonstrated using transient transfection assays. A high probability sumoylation consensus motif, VK(16)IE(18), is located within the N-terminal negative regulatory domain of Sp1. Either arginine substitution for lysine 16 (Sp1(K16R)) or alanine substitution for glutamic acid 18 (Sp1(E18A)), abrogated Sp1 sumoylation. In vitro SUMO-1 covalently bound affinity-purified GST-Sp1, but not GST-Sp1(K16R). In vivo Sp1 was determined to be N-terminally cleaved, while Sp1(K16R) could not be cleaved indicating that sumoylation and cleavage are coupled through the key regulatory lysine 16. This coupling was evident by the demonstration of an inverse relationship between cellular SUMO-modified Sp1 and N-terminally cleaved Sp1. Compared with Sp1, sumoylation-deficient Sp1(E18A) exhibited enhanced cleavage and was a better transcriptional activator, while constitutively SUMO-1-modified Sp1 was deficient in proteolytic processing and repressed Sp1 transcriptional activity. The repressive effect of sumoylation on Sp1 activity is emphasized through the use of a GAL4 based transactivation assay. A model is proposed defining a mechanism by which sumoylation preserves the integrity of a negative regulatory domain thereby allowing for the inhibition of Sp-dependent transcription.
Sp1是一种广泛表达的转录因子,可结合富含GC的顺式元件。许多翻译后修饰都与Sp1活性的调节有关。我们现在提供了一种涉及小泛素样修饰物(SUMO-1)的Sp1调节新机制的证据。蛋白质印迹分析显示,一种125 kDa的高分子量Sp1可被选择性SUMO水解酶抑制剂稳定,并被特异性SUMO-1水解酶破坏稳定性。使用瞬时转染试验证明了内源性SUMO-1和与绿色荧光蛋白融合的SUMO-1对Sp1的共价修饰。一个高概率的类泛素化共有基序VK(16)IE(18)位于Sp1的N端负调节域内。赖氨酸16被精氨酸取代(Sp1(K16R))或谷氨酸18被丙氨酸取代(Sp1(E18A))都会消除Sp1的类泛素化。在体外,SUMO-1与亲和纯化的GST-Sp1共价结合,但不与GST-Sp1(K16R)结合。在体内,Sp1被确定为N端被切割,而Sp1(K16R)不能被切割,这表明类泛素化和切割通过关键调节赖氨酸16偶联。细胞中SUMO修饰的Sp1和N端切割的Sp1之间呈负相关,证明了这种偶联关系。与Sp1相比,缺乏类泛素化的Sp1(E18A)表现出增强的切割,并且是更好的转录激活剂,而组成型SUMO-1修饰的Sp1在蛋白水解加工方面存在缺陷,并抑制Sp1转录活性。通过基于GAL4的反式激活试验强调了类泛素化对Sp1活性的抑制作用。提出了一个模型,定义了一种机制,通过该机制类泛素化保持负调节域的完整性,从而抑制Sp依赖性转录。